Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia



Status:Recruiting
Conditions:Other Indications, Blood Cancer
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:65 - Any
Updated:3/20/2019
Start Date:January 12, 2015

Use our guide to learn which trials are right for you!

A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

This phase II trial studies the side effects and how well blinatumomab and combination
chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with
acute lymphoblastic leukemia. Immunotherapy with blinatumomab, may induce changes in body's
immune system and may interfere with the ability of tumor cells to grow and spread. Drugs
used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and
mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more
cancer cells.

PRIMARY OBJECTIVES:

I. To evaluate the 3-year survival rate in elderly patients with newly diagnosed Philadelphia
(Ph)-negative acute lymphoblastic leukemia (ALL) treated with blinatumomab followed by POMP
(prednisone, vincristine sulfate, methotrexate, and mercaptopurine) maintenance.

II. To evaluate in a preliminary manner (feasibility study) the safety of dasatinib-steroid
based induction followed by blinatumomab treatment in combination with dasatinib followed by
dasatinib-based maintenance in patients with newly diagnosed Ph-positive ALL,
relapsed/refractory Ph-positive ALL, and Ph-like dasatinib-sensitive mutations or kinase
fusions (DSMKF) ALL (newly-diagnosed relapsed or refractory).

SECONDARY OBJECTIVES:

I. To evaluate toxicities in these patient populations treated with these regimens.

II. To estimate the rates of complete response (CR), complete remission with incomplete count
recovery (CRi) and disease-free survival in Ph-negative patients.

III. To estimate disease-free and overall survival in Ph-positive ALL and Ph-like DSMKF ALL.

IV. To estimate in each cohort the rate of minimal residual disease (MRD) negativity, and the
time to achieve MRD negativity (exploratory analysis).

V. To determine whether anti-idiotype antibodies directed against blinatumomab develop with
blinatumomab treatment in this study.

OUTLINE: Patients are assigned to 1 of 2 treatment cohorts according to Philadelphia
chromosome status.

COHORT I (PHILADELPHIA CHROMOSOME NEGATIVE PATIENTS):

INDUCTION: Patients receive blinatumomab intravenously (IV) continuously over 24 hours on
days 1-28 in the absence of disease progression or unacceptable toxicity.

RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV
continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable
toxicity.

POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28.
Treatment repeats every 42 days for 3 cycles in the absence of disease progression or
unacceptable toxicity.

MAINTENANCE: Patients receive prednisone orally (PO) on days 1-5, vincristine sulfate IV on
day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22.
Treatment repeats every 28 days for 18 cycles in the absence of disease progression or
unacceptable toxicity.

COHORT II (PHILADELPHIA CHROMOSOME POSITIVE PATIENTS):

INDUCTION: Patients receive dasatinib PO twice daily (BID) on days 1-84 and prednisone PO on
days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable
toxicity.

RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28.
Treatment repeats every 42 days for 2 cycles in the absence of disease progression or
unacceptable toxicity.

POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and
dasatinib PO once daily (QD) on days 1-42. Treatment repeats every 42 days for 3 cycles in
the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive dasatinib PO BID on days 1-28 and prednisone PO on days 1-5.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 2 years, and then annually until 10 years from initial registration.

Inclusion Criteria:

- Registration Step 1 - Induction/Re-Induction:

- Patients must have a new morphologic diagnosis of precursor B cell acute lymphoblastic
leukemia (ALL) (non T cell) based on World Health Organization (WHO) criteria;
patients with Burkitt's (L3) are excluded; patients with Ph-positive or Ph-like ALL
with dasatinib-sensitive mutations or kinase fusions may have relapsed or refractory
diagnoses

- NOTE: Relapsed/refractory Ph-positive patients or Ph-like patients with
dasatinib-sensitive mutations or kinase fusions who have previous exposure to
either dasatinib or another 2nd or 3rd generation tyrosine kinase inhibitor (TKI)
will begin protocol therapy with Cohort 2: re-induction cycle 1

- Patients must have a diagnosis of Philadelphia chromosome negative ALL or Ph
chromosome positive ALL by cytogenetics, fluorescence in situ hybridization (FISH) or
polymerase chain reaction (PCR); patients will be registered to receive treatment in
either Cohort 1 (ph-) or Cohort 2 (Ph+ or Ph-like DSMKF) based on these results;
diagnostic specimens must be submitted to the site's local Clinical Laboratory
Improvement Amendments (CLIA)-approved cytogenetics laboratory and results of tests
(cytogenetics, FISH or PCR) must confirm Ph status prior to registration; if not
already known, breakpoint cluster region- abelson murine leukemia viral oncogene
homolog 1 (BCR-ABL) status (p190 or p210) must be evaluated in Ph-positive patients by
PCR

- For Cohort 2, Ph-like testing is not required specifically for this study;
however, to be registered to Cohort 2 under the Ph-like DSMKF criterion, the
patient must have a known or presumed activating Ph-like signature and
dasatinib-sensitive mutation or kinase fusion, such as: ABL1, ABL2, colony
stimulating factor 1 receptor (CSF1R), platelet derived growth factor receptor
beta (PDGFRB), platelet derived growth factor receptor alpha (PDGFRA), or
fibroblast growth factor receptor (FGFR)s that was otherwise identified as part
of normal standard of care; prior to registering any patients with a known or
presumed activating Ph-like signature and dasatinib-sensitive mutations or kinase
fusions (DSMKF) treating physicians must confirm eligibility with the study
chairs via email; the study chairs must respond via email with confirmation of
patient eligibility prior to patient registration

- All newly diagnosed patients must have evidence of ALL in their marrow or peripheral
blood with at least 20% lymphoblasts present in blood or bone marrow collected within
28 days prior to registration; all relapsed/refractory patients (Cohort 2) must have
at least 5% lymphoblasts present in blood or bone marrow collected within 28 days
prior to registration; for relapsed/refractory patients, pathology and cytogenetics
reports (both from time of original diagnosis) must be submitted at time of
registration; if a bone marrow aspirate cannot be obtained despite an attempt (dry
tap), appropriate immunohistochemistry (IHC) testing, including CD19, must be
performed on the bone marrow biopsy to determine lineage; for ALL in marrow or
peripheral blood, immunophenotyping of the blood or marrow lymphoblasts must be
performed to determine lineage (B cell, T cell or mixed B/T cell); appropriate marker
studies including cluster of differentiation (CD)19 (B cell), must be performed;
co-expression of myeloid antigens (CD13 and CD33) will not exclude patients; if
possible, the lineage specific markers (myeloid cells) should be determined; the
blood/bone marrow sample for these assays must be obtained within 28 days prior to
registration; patients with only extramedullary disease in the absence of bone marrow
or blood involvement are not eligible

- Patient must not have a history or presence of clinically relevant central nervous
system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe
brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain
syndrome, psychosis, active ALL in the CNS confirmed by cerebrospinal fluid (CSF)
analysis, or other significant CNS abnormalities

- Patients must have a lumbar puncture to determine CNS involvement of ALL within 14
days prior to registration; patients with CNS3 are excluded from the trial; patients
with CNS1 or CNS2 will be eligible, but will be monitored for CNS involvement; note
that intrathecal methotrexate administered during the pre-study lumbar puncture may
count as the first dose of intrathecal therapy required as part of the study

- Cohort I, Ph-negative Patients Only

- Patients must not have received any prior chemotherapy, radiation therapy, or other
therapy for the treatment of ALL (other than those noted below) and must not be
receiving any immunosuppressive therapy; patients may not have received any prior
investigational therapy within 28 days prior to registration; patients must not have
received any monoclonal antibody therapy within 42 days of registration; patients may
have received the following within any time prior to registration: low dose
chemotherapy-including: cyclophosphamide 1 g/m^2, oral 6-mercaptopurine, or oral
methotrexate (other low dose chemotherapy may be allowable, however any other options
not listed here should be confirmed with the study chairs), TKI therapy, steroids,
hydroxyurea, leukapheresis, intrathecal chemotherapy or vincristine (vincristine
sulfate)

- In the event that the patient's bone marrow blast count is >= 50% blasts, patients may
be registered but should receive steroids for 3-5 days in order to reduce tumor burden
prior to blinatumomab administration, as follows

- Prephase treatment with dexamethasone (10-20 mg/m^2) for 3-5 days is required for
patients with bone marrow blasts >= 50%, peripheral blood blasts 15,000/uL or
higher, or elevated lactate dehydrogenase (LDH) suggesting rapidly progressive
disease per investigator opinion

- Pre-treatment should conclude at least 24 hours prior to the first dose of
blinatumomab (although additional dexamethasone is automatically given as a
pre-med prior to the first dose); at the time of first infusion of
blinatumomab, the absolute peripheral blast count should be < 25,000/uL

- Note: For the purposes of the study, day 1 of the cycle will be the first
day of blinatumomab administration

- It is preferred, but not required, that corticosteroids and hydroxyurea should start
only after all diagnostic samples have been obtained; however, if the patient was
previously on corticosteroids and/or hydroxyurea, this is allowable provided that the
patient still has measurable disease at time of the bone marrow aspirate

- Corticosteroids and/or hydroxyurea, as well as any of the other therapies
mentioned (with the exception of IV cyclophosphamide), may continue to be
administered, at physician discretion, until 1 day prior to blinatumomab
administration

- IV cyclophosphamide must be discontinued at least 7 days prior to
blinatumomab administration

- Patients must not be candidates for allogeneic hematopoietic stem cell transplant;
NOTE: Subjects up to age 70 years who are considered fit for allogeneic hematopoietic
stem cell transplant, should be considered for enrollment on E1910, in order to avoid
competing with that study; if a patient is considered unfit for intensive chemotherapy
at the time of initial diagnosis, but subsequently achieves a complete remission (CR),
then it will be left to the treating physician's discretion to consider hematopoietic
stem cell transplant (HSCT)

- Patients must have complete history and physical examination within 28 days prior to
registration

- Patients must have a Zubrod performance status of 0-2

- Patients must have serum creatinine =< 1.5 mg/dl within 14 days prior to registration

- Patients must have aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
=< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to
registration

- Patients must have total bilirubin =< 2.0 x IULN within 14 days prior to registration

- Patients must have alkaline phosphatase =< 2.5 x IULN within 14 days prior to
registration

- Patients must not have systemic fungal, bacterial, viral or other infection that is
not controlled (defined as exhibiting ongoing signs/symptoms related to the infection
and without improvement, despite appropriate antibiotics or other treatment)

- Patients must not have Common Terminology Criteria for Adverse Events (CTCAE) >= grade
2 neuropathy (cranial, motor or sensory) within 14 days prior to registration

- Patients known to be positive for HIV (the human immunodeficiency virus) may be
eligible, providing they meet the following additional criteria within 28 days prior
to registration:

- No history of acquired immune deficiency syndrome (AIDS)-defining conditions

- CD4 cells > 350 cells/mm^3

- If on antiretroviral agents, must not include zidovudine or stavudine

- Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on
combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if
not on cART

- Highly active antiretroviral therapy (HAART) regimens are acceptable providing
they have only weak P450A4 interactions

- Patients must not have any known autoimmune disease

- Patients must not have testicular involvement; if clinical or ultrasound findings are
equivocal, biopsy must be performed; all tests for establishing testicular involvement
must be completed within 14 days prior to registration

- Patients with evidence of extramedullary disease at diagnosis will have computed
tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen and
pelvis to obtain baseline values within 28 days prior to registration

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years

- Patients must have the following tests within 28 days prior to registration to obtain
baseline measurements:

- Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized
ratio (INR)/fibrinogen (all patients)

- Neurologic assessment

- Patients must have specimens submitted for blinatumomab immunogenicity assessment;
collection of pretreatment specimens must be completed within 28 days prior to
registration to S1318; specimens must be submitted to LabConnect

- Cohort 2, Ph-positive and Ph-like DSMKF Patients Only

- Patients must NOT have received a prior autologous or allogeneic hematopoietic stem
cell transplant at any time. Patients must NOT have received any chemotherapy,
investigational agents, or undergone major surgery within 14 days prior to
registration, with the following exceptions:

- Monoclonal antibodies must not have been received for 1 week prior to
registration

- Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days
prior to registration

- Steroids, hydroxyurea, vincristine, 6-mercaptopurine, methotrexate, thioguanine
and intrathecal chemotherapy are permitted within any timeframe prior to
registration; Food and Drug Administration (FDA)-approved TKIs may also be
administered until 1 day prior to start of study therapy (C1, D1); IV
cyclophosphamide may be administered at doses of 1 g/m^2 or less until up to 7
days prior to registration

- For patients 65-69 years of age, patient must be deemed not suitable for standard
intensive induction chemotherapy at the discretion of the local investigator, or must
have refused standard intensive chemotherapy

- Patients must not have active pericardial effusion, ascites or pleural effusion of any
grade based on chest x-ray and echocardiogram within 28 days prior to registration;
exception: if the effusion is suspected to be related to the leukemia, the patient may
have pericardial effusion =< grade 2 or pleural effusion =< grade 1

- Patients must have ejection fraction >= 45% based on echocardiogram performed within
28 days prior to registration

- Patients must have QTcF (by Fridericia calculation) < 480/msec based on
electrocardiogram (EKG) performed within 28 days prior to registration

- Patients must not be receiving any proton pump inhibitors at the time of registration

- Patients must agree to have specimens submitted for blinatumomab immunogenicity
testing if subsequently moved to a blinatumomab containing treatment regimen on
protocol

- Pretreatment cytogenetics must be performed on all patients; collection of
pretreatment specimens must be completed within 28 days prior to registration to
S1318; specimens must be submitted to the site's preferred CLIA-approved cytogenetics
laboratory; BCR-ABL status must be verified in Ph-positive patients by FISH,
cytogenetics, and/or PCR prior to enrollment; if a patient is Ph-positive, PCR for
both p190 and p210 must be sent

- Patients must be offered participation in specimen submission for future research;
with patient's consent, specimens must be submitted as outlined

- ALL PATIENTS: Patients or their legally authorized representative must be informed of
the investigational nature of this study and must sign and give written informed
consent in accordance with institutional and federal guidelines

- ALL PATIENTS: As a part of the Oncology Patient Enrollment Network (OPEN) registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system

- Registration Step 2 - Post-Remission Therapy:

- COHORT 1 PH-NEGATIVE PATIENTS ONLY: Patients must have achieved CR or CRi within 2
cycles of induction/re-induction with blinatumomab

- NOTE: day 1 of post-remission = day 43 of the preceding cycle (+/- 3 days)

- COHORT 2 PH-POSITIVE AND PH-LIKE DSMKF PATIENTS ONLY: Newly diagnosed Ph+,
newly-diagnosed Ph-like DSMKF, and relapsed/refractory Ph+ patients without prior
dasatinib or other 2nd or 3rd generation TKI therapy, must have achieved CR or CRi
within 1 cycle of induction with dasatinib/prednisone, or within 2 cycles of
re-induction with blinatumomab; relapsed/refractory Ph+ or Ph-like DSMKF patients with
prior dasatinib or other 2nd or 3rd generation TKI therapy must have achieved CR or
CRi within 2 cycles of re-induction therapy with blinatumomab

- NOTE: day 1 of post-remission = day 85 of the preceding induction cycle (+/- 3
days), or day 43 of the preceding re-induction cycle (+/- 3 days) as applicable

- Serum creatinine =< 1.5 mg/dl within 14 days prior to registration

- AST and ALT =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior
to registration

- Total bilirubin =< 2.0 x IULN within 14 days prior to registration

- Absolute neutrophil count (ANC
We found this trial at
198
sites
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Cecilia Y. Arana Yi
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Eunice S. Wang
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
1.800.422.9567
Principal Investigator: Micah M. Burch
Phone: 800-422-9567
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Ibrahim T. Aldoss
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Stephanie L. Elkins
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Jonathan E. Kolitz
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Patrick W. Burke
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Henry K. Holland
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
?
mi
from
Augusta, GA
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Maria R. Baer
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Principal Investigator: Krishna Gundabolu
Phone: 402-559-6941
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Nikolaos Papadantonakis
Phone: 205-934-0220
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bloomington, Illinois 61701
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
?
mi
from
Boone, IA
Click here to add this to my saved trials
Branson, Missouri 65616
?
mi
from
Branson, MO
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centerville, Ohio 45459
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Wendy Stock
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: John G. Quigley
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Aaron T. Gerds
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Bhavana Bhatnagar
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Crestview Hills, Kentucky 41017
?
mi
from
Crestview Hills, KY
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: James R. Egner
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
(937) 208-8000
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2222 Philadelphia Dr
Dayton, Ohio 45406
(937) 734-2612
Good Samaritan Hospital - Dayton Good Samaritan Hospital (GSH) is passionate about providing the most...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dayton, Ohio 45415
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2020 Central Ave
Dodge City, Kansas 67801
(620) 227-2488
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
Dodge City, KS
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Jeffrey Crawford
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Easley, SC
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: James R. Egner
Phone: 800-446-5532
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Effingham, IL
Click here to add this to my saved trials
700 West Central
El Dorado, Kansas 67042
(316) 889-0099
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - El Dorado Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
El Dorado, KS
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
309-467-2371
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Eureka, IL
Click here to add this to my saved trials
?
mi
from
Fairfield, OH
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
2601 Broadway
Fargo, North Dakota 58102
(701) 234-2900
Sanford Clinic North-Fargo Sanford Health is an integrated health system headquartered in the Dakotas and...
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
28050 Grand River Avenue
Farmington Hills, Michigan 48336
Principal Investigator: Ishmael A. Jaiyesimi
Phone: 248-551-7695
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
1900 S Main St
Findlay, Ohio 45840
(419) 423-4500
Blanchard Valley Hospital For more than 100 years, Blanchard Valley Hospital has made quality care...
?
mi
from
Findlay, OH
Click here to add this to my saved trials
Fort Dodge, Iowa 50501
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
?
mi
from
Fort Dodge, IA
Click here to add this to my saved trials
Fort Scott, Kansas 66701
(620) 223-8589
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas - Fort Scott Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Fort Scott, KS
Click here to add this to my saved trials
One Medical Center Drive
Franklin, Ohio 45005
(513) 424-2111
Atrium Medical Center - Middletown Regional Hospital Atrium Medical Center (Atrium) is built on the...
?
mi
from
Franklin, OH
Click here to add this to my saved trials
Galesburg, Illinois 61401
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
309-344-9269
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
Principal Investigator: Brian L. Burnette
Phone: 920-433-8889
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
1726 Shawano Avenue
Green Bay, Wisconsin 54303
Principal Investigator: Brian L. Burnette
Phone: 920-433-8889
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
835 S. Van Buren St.
Green Bay, Wisconsin 54301
(920) 884-3135
Principal Investigator: Brian L. Burnette
Phone: 920-433-8889
Green Bay Oncology at Saint Vincent Hospital We are one of a select few physician...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
1726 Shawano Ave.
Green Bay, Wisconsin 54303
(920) 884-3135
Principal Investigator: Brian L. Burnette
Phone: 920-433-8889
Green Bay Oncology Limited at Saint Mary's Hospital We are one of a select few...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
835 Sweitzer St
Greenville, Ohio 45331
(937) 548-1141
Wayne Hospital Stretching back to our roots nearly 100 years ago, Wayne HealthCare has always...
?
mi
from
Greenville, OH
Click here to add this to my saved trials
Greenville, South Carolina 29601
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
?
mi
from
Greenville, SC
Click here to add this to my saved trials
701 Grove Rd
Greenville, South Carolina 29605
(864) 455-7000
Greenville Memorial Hospital Greenville Memorial Medical Campus is a regional referral center for the diagnosis...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Greer, SC
Click here to add this to my saved trials
Grosse Pointe, Michigan 48230
Principal Investigator: Ishmael A. Jaiyesimi
Phone: 248-551-7695
?
mi
from
Grosse Pointe, MI
Click here to add this to my saved trials
800 W. Laurel
Independence, Kansas 67301
620-331-4099
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas-Independence Dr. H.E. Hynes founded Cancer Center of Kansas, P. A. in...
?
mi
from
Independence, KS
Click here to add this to my saved trials
8111 South Emerson Avenue
Indianapolis, Indiana 46237
Principal Investigator: John R. Edwards
Phone: 317-528-7060
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jefferson, Iowa 50129
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
?
mi
from
Jefferson, IA
Click here to add this to my saved trials
Jefferson City, Missouri 65109
?
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Joplin, Missouri 64804
?
mi
from
Joplin, MO
Click here to add this to my saved trials
1102 W 32nd St
Joplin, Missouri 64804
(417) 347-1111
Freeman Health System Freeman in Joplin, Missouri, is a 485-bed, three-hospital system providing comprehensive healthcare...
?
mi
from
Joplin, MO
Click here to add this to my saved trials
1521 Gull Rd
Kalamazoo, Michigan 49048
269) 226-7000
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Borgess Medical Center At Borgess, healing is our calling. This is the place where people...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Heather J. Male
Phone: 913-945-7552
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Kenansville, North Carolina 28349
Principal Investigator: Misbah U. Qadir
Phone: 252-559-2201
?
mi
from
Kenansville, NC
Click here to add this to my saved trials
3535 Southern Blvd
Kettering, Ohio 45429
(937) 298-4331
Kettering Medical Center Our flagship hospital, Kettering Medical Center, stands proudly in Kettering, Ohio. From...
?
mi
from
Kettering, OH
Click here to add this to my saved trials
205 Tenney St
Kewanee, Illinois 61443
309-852-0596
Illinois CancerCare - Kewanee Clinic Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer...
?
mi
from
Kewanee, IL
Click here to add this to my saved trials
750 Avenue D West
Kingman, Kansas 67068
(620) 532-3147
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Kingman Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Kingman, KS
Click here to add this to my saved trials
600 Moye Boulevard
Kinston, North Carolina 28501
Principal Investigator: Misbah U. Qadir
Phone: 252-559-2201
?
mi
from
Kinston, NC
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Matthew J. Wieduwilt
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
450 Lakeville Road
Lake Success, New York 11042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials